Mark A. Socinski, MD

Mark A. Socinski, MD

Executive Medical Director of the AdventHealth Cancer Institute, Medical Oncologist

Cancer

Mark A. Socinski

Overview

Dr. Mark A. Socinski is a board-certified, fellowship trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer. Dr. Socinski formerly served as Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials. He is the Executive Medical Director of the AdventHealth Cancer Institute.

Articles

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

NATURE MEDICINE

2023

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

CLINICAL CANCER RESEARCH

2023

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

The oncologist

2023

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials

JAMA ONCOLOGY

2023

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

FRONTIERS IN ONCOLOGY

2023

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

JOURNAL OF THORACIC ONCOLOGY

2022

['Poziotinib in Non-Small-Cell Lung Cancer Harboring', 'Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.']

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2022

A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer

EXPERT OPINION ON INVESTIGATIONAL DRUGS

2022

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

NATURE MEDICINE

2022

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

JOURNAL OF CLINICAL ONCOLOGY

2022

More Publication Information

Education & Training

Education

University of Vermont, Burlington, VT

Residency

Harvard Medical School/Beth Israel Hospital, Boston

Fellowship

Harvard Medical School/Beth Israel Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT04746924

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

Icon for trial | BGB-A317-A1217-302 A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Met

This study is currently enrolling.

This study will look at the efficacy and safety of combined treatment with 2 anticancer drugs, which are called tislelizumab (also known as BGB-A317) and BGB-A1217 compared to treatment with pembrolizumab and saline (a mix of s ...